Concerns with beta2-agonists in pediatric asthma - a clinical perspective

Paediatric Respiratory Reviews

Volumn 21, Issue , 2017, Pages 80-85

  Kersten, Elin T G ^a   Koppelman, Gerard H ^a   Thio, Bernard J ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Asthma; Genetic polymorphisms; Tolerance; 2 agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL; LONG ACTING BETA AGONIST; PLACEBO; SALMETEROL; UNCLASSIFIED DRUG; SALMETEROL XINAFOATE;

ADVERSE OUTCOME; ASTHMA; BETA ADRENERGIC STIMULATION; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CONTROLLED CLINICAL TRIAL (TOPIC); DESENSITIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REVIEW; CHILD; DOWN REGULATION; DRUG LABELING; ENDOTRACHEAL INTUBATION; GENETICS; HOSPITALIZATION; MORTALITY; PHARMACOGENETIC VARIANT; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; CHILD; CHILD, PRESCHOOL; DOWN-REGULATION; DRUG LABELING; HOSPITALIZATION; HUMANS; INTUBATION, INTRATRACHEAL; MORTALITY; PHARMACOGENOMIC VARIANTS; RECEPTORS, ADRENERGIC, BETA-2; SALMETEROL XINAFOATE;

EID: 84995608779     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2016.05.006     Document Type: Review

References (61)

1. [1] Bonini, M., di Mambro, C., Calderon, M.A., Compalati, E., Schunemann, H., Durham, S., et al. Beta-agonists for exercise-induced asthma. Cochrane Database Syst Rev, 10, 2013, CD003564.
2. [2] Johnson, M., Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117:1 (2006), 18–24.
3. [3] National Asthma Education and Prevention Program, Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 120:5 Suppl (2007), S94–S138.
4. [4] Global initiative for Asthma (GINA), From the Global Strategy for Asthma Managment and Prevention. 2014 Available from: http://www.ginasthma.org/.
5. [5] Szefler, S.J., Busse, W.W., The long-acting beta-adrenergic agonist controversy in asthma: troublesome times!. J Allergy Clin Immunol 130:6 (2012), 1256–1259.
6. [6] Salpeter, S.R., Wall, A.J., Buckley, N.S., Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events. Am J Med 123:4 (2010), 322–328.
7. [7] Wijesinghe, M., Weatherall, M., Perrin, K., Harwood, M., Beasley, R., Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J 34:4 (2009), 803–811.
8. [8] Cates, C.J., Cates, M.J., Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev(3), 2008, CD006363.
9. [9] Cates, C.J., Cates, M.J., Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev, 4, 2012, CD006923.
10. [10] McMahon, A.W., Levenson, M.S., McEvoy, B.W., Mosholder, A.D., Murphy, D., Age and risks of FDA-approved long-acting beta(2)-adrenergic receptor agonists. Pediatrics 128:5 (2011), e1147–e1154.
11. [11] Weatherall, M., Wijesinghe, M., Perrin, K., Harwood, M., Beasley, R., Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 65:1 (2010), 39–43.
12. [12] Bisgaard, H., Szefler, S., Long-acting beta2 agonists and paediatric asthma. Lancet 367:9507 (2006), 286–288.
13. [13] Peachell, P., Regulation of mast cells by beta-agonists. Clin Rev Allergy Immunol 31:2–3 (2006), 131–142.
14. [14] Broadley, K.J., Beta-adrenoceptor responses of the airways: for better or worse?. Eur J Pharmacol 533:1–3 (2006), 15–27.
15. [15] Schutzer, W.E., Mader, S.L., Age-related changes in vascular adrenergic signaling: clinical and mechanistic implications. Ageing Res Rev 2:2 (2003), 169–190.
16. [16] Meurs, H., Kauffman, H.F., Koeter, G.H., Timmermans, A., de, V.K., Regulation of the beta-receptor-adenylate cyclase system in lymphocytes of allergic patients with asthma: possible role for protein kinase C in allergen-induced nonspecific refractoriness of adenylate cyclase. J Allergy Clin Immunol 80:3 Pt 1 (1987), 326–339.
17. [17] Stolley, P.D., Asthma, mortality., Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 105:6 (1972), 883–890.
18. [18] Crane, J., Pearce, N., Flatt, A., Burgess, C., Jackson, R., Kwong, T., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1:8644 (1989), 917–922.
19. [19] Suissa, S., Ernst, P., Boivin, J.F., Horwitz, R.I., Habbick, B., Cockroft, D., et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 149:3 Pt 1 (1994), 604–610.
20. [20] Sears, M.R., Taylor, D.R., Print, C.G., Lake, D.C., Li, Q.Q., Flannery, E.M., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336:8728 (1990), 1391–1396.
21. [21] Walters, E.H., Walters, J., Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment. Cochrane Database Syst Rev(2), 2003, CD001285.
22. [22] Castle, W., Fuller, R., Hall, J., Palmer, J., Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306:6884 (1993), 1034–1037.
23. [23] Nelson, H.S., Weiss, S.T., Bleecker, E.R., Yancey, S.W., Dorinsky, P.M., The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:1 (2006), 15–26.
24. [24] Jaeschke, R., O'Byrne, P.M., Mejza, F., Nair, P., Lesniak, W., Brozek, J., et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 178:10 (2008), 1009–1016.
25. [25] Cates, C.J., Jaeschke, R., Schmidt, S., Ferrer, M., Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev, 6, 2013, CD006924.
26. [26] Cates, C.J., Jaeschke, R., Schmidt, S., Ferrer, M., Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev, 3, 2013, CD006922.
27. [27] Nelson, H., Bonuccelli, C., Radner, F., Ottosson, A., Carroll, K.J., Andersson, T.L., et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 125:2 (2010), 390–396.
28. [28] Price, J.F., Radner, F., Lenney, W., Lindberg, B., Safety of formoterol in children and adolescents: experience from asthma clinical trials. Arch Dis Child 95:12 (2010), 1047–1053.
29. [29] Cates, C.J., Oleszczuk, M., Stovold, E., Wieland, L.S., Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev, 10, 2012, CD010005.
30. [30] Chauhan, B.F., Ducharme, F.M., Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev, 1, 2014, CD003137.
31. [31] Ducharme, F.M., Ni Chroinin, M., Greenstone, I., Lasserson, T.J., Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev, 4, 2010, CD005533.
32. [32] Chowdhury, B.A., Dal, P.G., The, F.D.A., and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma. N Engl J Med 362:13 (2010), 1169–1171.
33. [33] Barnes, P.J., Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 19:1 (2002), 182–191.
34. [34] Tan, K.S., Grove, A., McLean, A., Gnosspelius, Y., Hall, I.P., Lipworth, B.J., Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 156:1 (1997), 28–35.
35. [35] Aziz, I., Lipworth, B.J., A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. Chest 115:3 (1999), 623–628.
36. [36] Simons, F.E., Gerstner, T.V., Cheang, M.S., Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 99:5 (1997), 655–659.
37. [37] Fogel, R.B., Rosario, N., Aristizabal, G., Loeys, T., Noonan, G., Gaile, S., et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 104:6 (2010), 511–517.
38. [38] Storms, W., Chervinsky, P., Ghannam, A.F., Bird, S., Hustad, C.M., Edelman, J.M., A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 98:11 (2004), 1051–1062.
39. [39] Agarwal, S.K., Marshall, G.D. Jr., Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol 105:1 Pt 1 (2000), 91–98.
40. [40] Aldridge, R.E., Hancox, R.J., Taylor, R.D., Cowan, J.O., Winn, M.C., Frampton, C.M., et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 161:5 (2000), 1459–1464.
41. [41] Nino, G., Hu, A., Grunstein, J.S., Grunstein, M.M., Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 297:4 (2009), L746–L757.
42. [42] McGraw, D.W., Almoosa, K.F., Paul, R.J., Kobilka, B.K., Liggett, S.B., Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 112:4 (2003), 619–626.
43. [43] Sindi, A., Todd, D.C., Nair, P., Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and metaanalysis. Chest 136:1 (2009), 145–154.
44. [44] Hawkins, G.A., Tantisira, K., Meyers, D.A., Ampleford, E.J., Moore, W.C., Klanderman, B., et al. Sequence, haplotype, and association analysis of ADR(2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 174:10 (2006), 1101–1109.
45. [45] Green, S.A., Turki, J., Bejarano, P., Hall, I.P., Liggett, S.B., Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 13:1 (1995), 25–33.
46. [46] Israel, E., Chinchilli, V.M., Ford, J.G., Boushey, H.A., Cherniack, R., Craig, T.J., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364:9444 (2004), 1505–1512.
47. [47] Hancox, R.J., Sears, M.R., Taylor, D.R., Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 11:3 (1998), 589–593.
48. [48] Taylor, D.R., Drazen, J.M., Herbison, G.P., Yandava, C.N., Hancox, R.J., Town, G.I., Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 55:9 (2000), 762–767.
49. [49] Bleecker, E.R., Postma, D.S., Lawrance, R.M., Meyers, D.A., Ambrose, H.J., Goldman, M., Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370:9605 (2007), 2118–2125.
50. [50] Wechsler, M.E., Kunselman, S.J., Chinchilli, V.M., Bleecker, E., Boushey, H.A., Calhoun, W.J., et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374:9703 (2009), 1754–1764.
51. [51] Lee, D.K., Currie, G.P., Hall, I.P., Lima, J.J., Lipworth, B.J., The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 57:1 (2004), 68–75.
52. [52] Bonini, M., Permaul, P., Kulkarni, T., Kazani, S., Segal, A., Sorkness, C.A., et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and FeNO. Am J Respir Crit Care Med 188:12 (2013), 1407–1412.
53. [53] Basu, K., Palmer, C.N., Tavendale, R., Lipworth, B.J., Mukhopadhyay, S., Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 124:6 (2009), 1188–1194.
54. [54] Zuurhout, M.J., Vijverberg, S.J., Raaijmakers, J.A., Koenderman, L., Postma, D.S., Koppelman, G.H., et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the pacman cohort. Pharmacogenomics 14:16 (2013), 1965–1971.
55. [55] Lipworth, B.J., Basu, K., Donald, H.P., Tavendale, R., Macgregor, D.F., Ogston, S.A., et al. Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clin Sci (Lond) 124:8 (2013), 521–528.
56. [56] Jenkins, H.A., Cherniack, R., Szefler, S.J., Covar, R., Gelfand, E.W., Spahn, J.D., A comparison of the clinical characteristics of children and adults with severe asthma. Chest 124:4 (2003), 1318–1324.
57. [57] Gelfand, E.W., Pediatric asthma: a different disease. Proc Am Thorac Soc 6:3 (2009), 278–282.
58. [58] Vilozni, D., Szeinberg, A., Barak, A., Yahav, Y., Augarten, A., Efrati, O., The relation between age and time to maximal bronchoconstriction following exercise in children. Respir Med 103:10 (2009), 1456–1460.
59. [59] Mochizuki, H., Shigeta, M., Kato, M., Maeda, S., Shimizu, T., Mirokawa, A., Age-related changes in bronchial hyperreactivity to methacholine in asthmatic children. Am J Respir Crit Care Med 152:3 (1995), 906–910.
60. [60] van Leeuwen, J.C., Driessen, J.M., de Jongh, F.H., Anderson, S.D., Thio, B.J., Measuring breakthrough exercise-induced bronchoconstriction in young asthmatic children using a jumping castle. J Allergy Clin Immunol 131:5 (2013), 1427–1429.
61. [61] Moorman, J.E., Rudd, R.A., Johnson, C.A., King, M., Minor, P., Bailey, C., et al. National surveillance for asthma—United States, 1980-2004. MMWR Surveill Summ 56:8 (2007), 1–54.